The ELF portfolio covers various target classes, and this case study focuses on a Gi/Gq-linked GPCR related to neuropathic pain.

Researchers used a cell line that stably expresses the target to screen approximately 400,000 compounds in a FLIPR assay. They identified 87 potential hit compounds, many of which confirmed activity in the DMR assay with good correlation to the FLIPR assay.